Filing Details

Accession Number:
0001209191-22-003046
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-12 16:05:27
Reporting Period:
2022-01-10
Accepted Time:
2022-01-12 16:05:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1388773 Laura Clague C/O Travere Therapeutics, Inc.
3611 Valley Centre Dr., Suite 300
San Diego CA 92130
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-10 7,500 $0.00 38,816 No 4 A Direct
Common Stock Disposition 2022-01-11 7,500 $27.40 31,316 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
  2. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.